Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
AssigneeBoehringer Ingelheim Vetmedica GmbH
InventorsMichael Roof, Marc Eichmeyer
Life of this patent
Estimating the term…
Abstract
Multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of M. hyo infection, preferably M. hyo bacterin, or an immunogenic composition comprising M. hyo bacterin, and at least one immunogenic active component of another disease-causing organism in swine, preferably PCV2 wherein the preferred PCV2 antigen for such a multivalent vaccine is PCV2 ORF 2 protein.
Claims26
An immunogenic composition for eliciting a protective immune response in a pig against Mycoplasma hyopneumoniae (M. hyo) wherein said immunogenic composition comprises porcine circovirus type 2 antigen and M. hyo antigen, wherein the amount of the M. hyo antigen per dose has a relative potency (RP) value of at least 1.22, wherein an RP value of 1.22 for M. hyo means that 95% and preferably 100% of mice receiving an administration of one-fortieth (1/40) of such amount of M. hyo antigen develop a detectable amount of antibodies within or at 21 days post treatment in an M. hyo specific antibody detection assay.
A method for eliciting a protective immune response in a pig against Mycoplasma hyopneumoniae (M. hyo) comprising administering to said pig an immunogenic composition which comprises porcine circovirus type 2 antigen and M. hyo antigen, wherein the amount of the M. hyo antigen per dose has a relative potency value of at least 1.22, wherein an RP value of 1.22 for M. hyo means that 95% and preferably 100% of mice receiving an administration of one-fortieth ( 1/40) of such amount of M. hyo antigen develop a detectable amount of antibodies within or at 21 days post treatment in an M. hyo specific antibody detection assay.
Dependencies are inferred from the claim text.